| Identification | Back Directory | [Name]
Soticlestat | [CAS]
1429505-03-2 | [Synonyms]
OV935
TAK-935
Soticlestat
Methanone, [2,4'-bipyridin]-3-yl[4-hydroxy-4-(phenylmethyl)-1-piperidinyl]- | [Molecular Formula]
C23H23N3O2 | [MDL Number]
MFCD33548812 | [MOL File]
1429505-03-2.mol | [Molecular Weight]
373.45 |
| Hazard Information | Back Directory | [Uses]
Soticlestat (TAK-935; OV935) is a first-in-class, potent, selective, and orally active cholesterol 24-hydroxylase (CH24H) inhibitor. Soticlestat has the potential for epilepsy syndromes research[1][2]. | [in vivo]
Soticlestat treatment lowers brain 24S-hydroxycholesterol in a dose-dependent manner and substantially reduceds premature deaths of APP/PS1-Tg mice at a dose lowering brain 24S-hydroxycholesterol by approximately 50%. Soticlestat can suppress potassium-evoked extracellular glutamate elevations in the hippocampus[1]. | Animal Model: | Amyloid precursor protein and presenilin 1 (APP/PS1-Tg) mice (7-week-old)[1] | | Dosage: | 10 mg/kg | | Administration: | Oral administration; once daily; for 1 days, 3 days and 7 days | | Result: | Lowered brain 24S-hydroxycholesterol in a dose-dependent manner and substantially reduced premature deaths of APP/PS1-Tg mice at a dose lowering brain 24S-hydroxycholesterol by approximately 50%. |
| [References]
[1] Toshiya Nishi, et al. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. Sci Rep. 2020 Oct 13;10(1):17081. DOI:10.1038/s41598-020-74036-6
[2] Krista Eschbach, et al. Stiripentol for the treatment of seizures in Dravet syndrome. Expert Rev Clin Pharmacol. 2019 May;12(5):379-388. DOI:10.1080/17512433.2019.1605904 |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
http://m.is0513.com/ShowSupplierProductsList927327/0.htm |
|